Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 23, 2026, 8:23 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 505–528 of 924 matching trials from the live ClinicalTrials.gov search.
Conditions
Plaque Psoriasis
Interventions
LCD Solution with NB-UVB Phototherapy, NB-UVB Light Device (311-315 nm)
Other · Device
Lead sponsor
NeoStrata Company, Inc.
Industry
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
East Windsor, New Jersey
Conditions
Psoriasis
Interventions
DFD06 Cream, Clobetasol Propionate Cream 0.05%
Drug
Lead sponsor
Promius Pharma, LLC
Industry
Eligibility
18 Years to 90 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
15
States / cities
Glendale, Arizona • Mesa, Arizona • Encino, California + 11 more
Conditions
Moderate to Severe Plaque Psoriasis
Interventions
bimekizumab
Drug
Lead sponsor
UCB Biopharma SRL
Industry
Eligibility
12 Years to 17 Years
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
2
States / cities
Indianapolis, Indiana • Cypress, Texas
Conditions
Moderate and Severe Plaque Psoriasis
Interventions
Placebo, AEB071
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
336 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2009
U.S. locations
10
States / cities
Hot Springs, Arizona • Pinellas Park, Florida • Overland Park, Kansas + 6 more
Conditions
Moderate-to-severe Chronic Plaque Psoriasis
Interventions
Tildrakizumab, Placebo, Etanercept
Drug
Lead sponsor
Sun Pharmaceutical Industries Limited
Industry
Eligibility
6 Years to 215 Months
Enrollment
135 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2031
U.S. locations
5
States / cities
Fountain Valley, California • Thousand Oaks, California • Miami, Florida + 1 more
Conditions
Arthritis, Psoriatic
Interventions
Guselkumab, Placebo
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
383 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
9
States / cities
Birmingham, Alabama • Glendale, Arizona • Mesa, Arizona + 6 more
Conditions
Psoriasis, Plaque-type Psoriasis
Interventions
secukinumab, placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
12
States / cities
Birmingham, Alabama • Pasadena, California • Indianapolis, Indiana + 9 more
Conditions
Atopic Dermatitis, Psoriasis
Interventions
YR001 Dose A on low body surface area, YR001 Dose A on middle body surface area, YR001 Dose A on high body surface area, YR001 Dose B on low body surface area, YR001 Dose B on middle body surface area, YR001 Dose B on high body surface area, Placebo on low body surface area, Placebo on middle body surface area, Placebo on high body surface area, YR001 Dose A on high body surface area twice daily, YR001 Dose B on high body surface area twice daily, Placebo on high body surface area twice daily
Drug
Lead sponsor
Hangzhou Yirui Pharmaceutical Technology Co., Ltd
Industry
Eligibility
18 Years to 65 Years
Enrollment
54 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
Encinitas, California
Conditions
Plaque Psoriasis
Interventions
Tapinarof Cream, 1%, Vtama® (Tapinarof) Cream, 1%, Placebo Control
Drug
Lead sponsor
Sun Pharmaceutical Industries, Inc.
Industry
Eligibility
18 Years and older
Enrollment
575 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Hawthorne, New York
Completed Phase 4 Interventional Accepts healthy volunteers Results available

A Study to Assess Efficacy and Tolerability of Topical Skincare Products on Psoriasis Patients

NCT06357221
Conditions
Plaque Psoriasis, Psoriasis
Interventions
Cetaphil
Drug
Lead sponsor
Galderma R&D
Industry
Eligibility
18 Years and older
Enrollment
46 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
3
States / cities
Columbus, Georgia • Douglasville, Georgia • High Point, North Carolina
Conditions
Moderate to Severe Chronic Plaque Psoriasis
Interventions
DMB-3115, Stelara
Drug
Lead sponsor
Dong-A ST Co., Ltd.
Industry
Eligibility
18 Years to 75 Years
Enrollment
598 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
2
States / cities
Norman, Oklahoma • West Jordan, Utah
Completed Phase 4 Interventional Results available

Apremilast in Palmo-Plantar Psoriasis

NCT02400749
Conditions
Palmo-plantar Psoriasis
Interventions
Apremilast, Placebo
Drug
Lead sponsor
Innovaderm Research Inc.
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Arlington Heights, Illinois
Completed No phase listed Observational Accepts healthy volunteers

Molecular and Cellular Characterization of Spongiotic Dermatitis

NCT00371163
Conditions
Atopic Dermatitis, Psoriasis, Contact Dermatitis
Interventions
Not listed
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years to 55 Years
Enrollment
31 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2012
U.S. locations
1
States / cities
Sacramento, California
Active, not recruiting Phase 2 Interventional

A Study of SPY072 in Rheumatic Disease

NCT07148414
Conditions
Rheumatoid Arthritis, Psoriatic Arthritis, Axial Spondyloarthritis, Rheumatic Diseases, Rheumatic Joint Disease, PsA (Psoriatic Arthritis), AxSpA, Rheumatologic Disease
Interventions
SPY002-072, Placebo
Drug
Lead sponsor
Spyre Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
285 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
18
States / cities
Avondale, Arizona • Tucson, Arizona • Chula Vista, California + 14 more
Active, not recruiting No phase listed Observational

Psoriasis Longitudinal Assessment and Registry

NCT00508547
Conditions
Psoriasis
Interventions
Not listed
Lead sponsor
Janssen Scientific Affairs, LLC
Industry
Eligibility
18 Years to 99 Years
Enrollment
20,167 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2030
U.S. locations
167
States / cities
Birmingham, Alabama • Florence, Alabama • Huntsville, Alabama + 164 more
Conditions
Plaque Psoriasis
Interventions
roflumilast cream 0.3%, Zoryve, Placebo
Drug
Lead sponsor
Padagis LLC
Industry
Eligibility
12 Years to 75 Years
Enrollment
416 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023
U.S. locations
1
States / cities
Louisville, Kentucky
Conditions
Plaque Psoriasis
Interventions
PH-10 (rose bengal disodium 0.001%), Control
Drug
Lead sponsor
Provectus Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
New York, New York
Conditions
Palmoplantar Pustulosis (PPP)
Interventions
Spesolimab, Placebo
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years to 75 Years
Enrollment
152 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
14
States / cities
Birmingham, Alabama • Beverly Hills, California • San Diego, California + 11 more
Conditions
Plaque Psoriasis
Interventions
PF-06826647 tablet, PF-06826647 oral suspension, Placebo oral solution/suspension, Placebo tablet
Drug · Other
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
109 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
1
States / cities
Anaheim, California
Conditions
Moderate Plaque Psoriasis
Interventions
Risankizumab, Deucravacitinib
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
393 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
39
States / cities
Birmingham, Alabama • Glendale, Arizona • Scottsdale, Arizona + 32 more
Conditions
Psoriasis
Interventions
Enstilar
Drug
Lead sponsor
Psoriasis Treatment Center of Central New Jersey
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
East Windsor, New Jersey
Conditions
Plaque Type Psorisis
Interventions
Tapinarof Cream 1%, VTAMA®, Placebo
Drug
Lead sponsor
Teva Pharmaceuticals USA
Industry
Eligibility
18 Years and older
Enrollment
560 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
26
States / cities
Scottsdale, Arizona • Bryant, Arkansas • Dublin, California + 20 more
Conditions
Psoriasis, Cardiovascular Diseases, Dyslipidemia
Interventions
Not listed
Lead sponsor
George Washington University
Other
Eligibility
18 Years to 80 Years
Enrollment
210 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2016
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Conditions
Psoriasis
Interventions
Apremilast, Placebo
Drug · Other
Lead sponsor
Amgen
Industry
Eligibility
18 Years and older
Enrollment
289 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
26
States / cities
Birmingham, Alabama • Fountain Valley, California • Santa Monica, California + 23 more